The role of androgen receptors (ARs) registration in cytosol tumor fraction has been investigated in 86 new cases of prostatic cancer. The frequency of occurrence and mean ARs levels in the tumor were found dependent on the disease stage and tumor differentiation. Well-differentiated against moderately and poorly differentiated prostatic cancers contain ARs in 73% and 39% of cases, respectively, in concentrations 10-100 fmol/mg protein and 100 fmol/mg protein, respectively. Patients with well-differentiated prostatic cancer at stage T1-4N0M0 and 10-100 fmol/mg protein ARs in the tumor tend to achieve longer remissions compared to patients with ARs-free tumors or tumor comprising ARs in concentrations surpassing 100 fmol/mg protein. No significant correlation exists between remission duration in patients on radiation treatment combined with estrogen therapy and the presence, levels of ARs in the tumor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
Lancet Oncol
September 2024
Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
Background: Breast-conserving surgery, adjuvant systemic therapy, and radiotherapy are the standard of care for most women with early breast cancer. There are few reports of clinical outcomes beyond the first decade of follow-up of randomised trials comparing breast-conserving surgery with or without radiotherapy. We present a 30-year update of the Scottish Breast Conservation Trial.
View Article and Find Full Text PDFAlbumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma.
Mol Pharm
June 2024
Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States.
Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads.
View Article and Find Full Text PDFDesign of a New Tc-radiolabeled Cyclo-peptide as Promising Molecular Imaging Agent of CXCR Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation.
Curr Radiopharm
May 2024
Department of Pharmacology and Toxicology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Introduction: C-X-C Chemokine receptor type 4 (CXCR4) is often overexpressed or overactivated in different types and stages of cancer disease. Therefore, it is considered a promising target for imaging and early detection of primary tumors and metastasis. In the present research, a new cyclo-peptide radiolabelled with Tc, Tc-Cyclo [D-Phe-D-Tyr-Lys (HYNIC)- D-Arg-2-Nal-Gly-Lys(iPr)], was designed based on the parental LY251029 peptide, as a potential imaging agent of CXCR4-expressing tumors.
View Article and Find Full Text PDFBinding Parameters of [C]MPC-6827, a Microtubule-Imaging PET Radiopharmaceutical in Rodents.
Pharmaceuticals (Basel)
March 2023
Department of Radiology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.
Impairment and/or destabilization of neuronal microtubules (MTs) resulting from hyper-phosphorylation of the tau proteins is implicated in many pathologies, including Alzheimer's disease (AD), Parkinson's disease and other neurological disorders. Increasing scientific evidence indicates that MT-stabilizing agents protect against the deleterious effects of neurodegeneration in treating AD. To quantify these protective benefits, we developed the first brain-penetrant PET radiopharmaceutical, [C]MPC-6827, for quantification of MTs in rodent and nonhuman primate models of AD.
View Article and Find Full Text PDFLower levels of cortical [H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits.
Schizophr Res
May 2023
Melbourne Veterinary School, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria, Australia.
Multiple lines of evidence argue for lower levels of cortical muscarinic M1 receptors (CHRM1) in people with schizophrenia which is possibly due to a sub-group within the disorder who have a marked loss of CHRM1 (muscarinic receptor deficit sub-group (MRDS)). In this study we sought to determine if the lower levels of CHRM1 was apparent in older people with schizophrenia and whether the loss of CHRM1 was associated with symptom severity by measuring levels of cortical [H]pirenzepine binding to CHRM1 from 56 people with schizophrenia and 43 controls. Compared to controls (173 ± 6.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!